• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

携带上皮生长因子受体突变且微小RNA - 135b过表达的外周型肺腺癌更易侵犯脏层胸膜。

Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura.

作者信息

Le Hanbo, Wang Xiaoling, Zha Yao, Wang Jie, Zhu Wangyu, Ye Zhinan, Liu Xiaoguang, Ma Haijie, Zhang Yongkui

机构信息

Department of Cardio-Thoracic Surgery, Lung Cancer Research Center, The Affiliated Zhoushan Hospital of Wenzhou Medical University, Zhoushan, Zhejiang 316004, P.R. China.

Laboratory of Cytobiology and Molecular Biology, The Affiliated Zhoushan Hospital of Wenzhou Medical University, Zhoushan, Zhejiang 316004, P.R. China.

出版信息

Oncol Lett. 2017 Dec;14(6):7931-7940. doi: 10.3892/ol.2017.7195. Epub 2017 Oct 16.

DOI:10.3892/ol.2017.7195
PMID:29250182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5727608/
Abstract

Lung adenocarcinoma, characterized by its early and aggressive local invasion and high metastatic potential, is the most frequently observed histological type of non-small-cell lung cancer (NSCLC). Visceral pleural invasion (VPI) caused by peripheral lung adenocarcinomas is closely associated with the poor prognosis of patients with NSCLC. The association between VPI and some clinicopathological characteristics has been observed in the past few decades. However, the molecular mechanism of VPI in lung adenocarcinomas is unknown. In the present, the expression level of microRNA (miR-)135b and epidermal growth factor receptor (EGFR) mutations using the reverse transcription-quantitative polymerase chain reaction and DNA sequencing, respectively. In addition, the present study aimed at exploring the association between the miR-135b level, EGFR mutations and VPI in peripheral lung adenocarcinoma. The results of the present study demonstrated that miR-135b was significantly upregulated in lung adenocarcinoma compared with adjacent normal tissue and positively associated EGFR mutations in peripheral lung adenocarcinoma. Furthermore, it was identified that lung adenocarcinomas with EGFR mutations and miR-135b overexpression were more likely to invade visceral pleura. Taken together, these findings indicate that miR-135b overexpression is positively associated with mutations to EGFR, which may promote the development of peripheral lung adenocarcinomas by the formation of VPI. This indicates that the two factors may serve as prognostic markers and molecular targets for the treatment of peripheral lung adenocarcinomas.

摘要

肺腺癌是最常见的非小细胞肺癌(NSCLC)组织学类型,其特点是早期发生侵袭性局部侵犯且具有高转移潜能。外周型肺腺癌引起的脏层胸膜侵犯(VPI)与NSCLC患者的不良预后密切相关。在过去几十年中,人们已经观察到VPI与一些临床病理特征之间的关联。然而,肺腺癌中VPI的分子机制尚不清楚。目前,分别使用逆转录定量聚合酶链反应和DNA测序检测微小RNA(miR-)135b的表达水平和表皮生长因子受体(EGFR)突变情况。此外,本研究旨在探讨外周型肺腺癌中miR-135b水平、EGFR突变与VPI之间的关联。本研究结果表明,与相邻正常组织相比,miR-135b在肺腺癌中显著上调,并且与外周型肺腺癌中的EGFR突变呈正相关。此外,研究发现具有EGFR突变和miR-135b过表达的肺腺癌更易侵犯脏层胸膜。综上所述,这些发现表明miR-135b过表达与EGFR突变呈正相关,这可能通过形成VPI促进外周型肺腺癌的发展。这表明这两个因素可能作为外周型肺腺癌治疗的预后标志物和分子靶点。

相似文献

1
Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura.携带上皮生长因子受体突变且微小RNA - 135b过表达的外周型肺腺癌更易侵犯脏层胸膜。
Oncol Lett. 2017 Dec;14(6):7931-7940. doi: 10.3892/ol.2017.7195. Epub 2017 Oct 16.
2
Novel biologic factors correlated to visceral pleural invasion in early-stage non-small cell lung cancer less than 3 cm.与直径小于3cm的早期非小细胞肺癌脏层胸膜侵犯相关的新型生物因子。
J Thorac Dis. 2018 Apr;10(4):2357-2364. doi: 10.21037/jtd.2018.03.185.
3
mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients.突变与非小细胞肺癌患者的脏层胸膜侵犯发展显著相关。
Cancer Manag Res. 2019 Mar 1;11:1945-1957. doi: 10.2147/CMAR.S195747. eCollection 2019.
4
Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.具有 KRAS 突变的周围型肺腺癌更有可能侵犯内脏胸膜。
Arch Pathol Lab Med. 2015 Feb;139(2):189-93. doi: 10.5858/arpa.2013-0759-OA. Epub 2014 Apr 2.
5
[Prognostic study of visceral pleural invasion by pulmonary adenocarcinoma with tumor size ≤3 cm].[肿瘤大小≤3cm的肺腺癌脏层胸膜侵犯的预后研究]
Zhonghua Bing Li Xue Za Zhi. 2017 Aug 8;46(8):553-558. doi: 10.3760/cma.j.issn.0529-5807.2017.08.007.
6
Predictive CT Features of Visceral Pleural Invasion by T1-Sized Peripheral Pulmonary Adenocarcinomas Manifesting as Subsolid Nodules.表现为亚实性结节的T1期周围型肺腺癌脏层胸膜侵犯的CT预测特征
AJR Am J Roentgenol. 2017 Sep;209(3):561-566. doi: 10.2214/AJR.16.17280. Epub 2017 Jun 22.
7
EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.原发性肺腺癌及相应转移灶中 EGFR 突变状态:胸膜转移中的不一致性。
Clin Lung Cancer. 2011 Nov;12(6):380-6. doi: 10.1016/j.cllc.2011.02.006. Epub 2011 May 20.
8
Prognostic impact of microscopic vessel invasion and visceral pleural invasion and their correlations with epithelial-mesenchymal transition, cancer stemness, and treatment failure in lung adenocarcinoma.肺腺癌中微血管侵犯和内脏胸膜侵犯的预后影响及其与上皮-间充质转化、癌症干性和治疗失败的相关性。
Lung Cancer. 2019 Feb;128:13-19. doi: 10.1016/j.lungcan.2018.12.001. Epub 2018 Dec 6.
9
Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor.非小细胞肺癌侵犯脏层胸膜:一个被低估的不良预后因素。
Ann Thorac Surg. 2001 Apr;71(4):1088-93. doi: 10.1016/s0003-4975(00)02649-7.
10
Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer.手术切除淋巴结阴性非小细胞肺癌的内脏胸膜侵犯程度与预后。
Thorac Cancer. 2017 May;8(3):197-202. doi: 10.1111/1759-7714.12424. Epub 2017 Feb 21.

引用本文的文献

1
miR-135b: A key role in cancer biology and therapeutic targets.微小RNA-135b:在癌症生物学及治疗靶点中起关键作用
Noncoding RNA Res. 2025 Feb 20;12:67-80. doi: 10.1016/j.ncrna.2025.02.005. eCollection 2025 Jun.
2
A review on the importance of miRNA-135 in human diseases.关于miRNA - 135在人类疾病中的重要性的综述。
Front Genet. 2022 Sep 6;13:973585. doi: 10.3389/fgene.2022.973585. eCollection 2022.
3
Rethinking the Selection of Pathological T-Classification for Non-Small-Cell Lung Cancer in Varying Degrees of Visceral Pleural Invasion: A SEER-Based Study.重新思考不同程度脏层胸膜侵犯的非小细胞肺癌病理T分类的选择:一项基于监测、流行病学和最终结果(SEER)数据库的研究
Front Surg. 2022 May 19;9:902710. doi: 10.3389/fsurg.2022.902710. eCollection 2022.
4
MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential.肺癌中的微小RNA:诊断、预后及治疗潜力
Diagnostics (Basel). 2022 Jul 1;12(7):1610. doi: 10.3390/diagnostics12071610.
5
[Clinical Characteristics and Risk Factors Analysis for Visceral Pleural Invasion in 
Mixed Ground-glass Nodular Lung Adenocarcinoma].[混合性磨玻璃结节型肺腺癌脏层胸膜侵犯的临床特征及危险因素分析]
Zhongguo Fei Ai Za Zhi. 2022 Apr 20;25(4):236-244. doi: 10.3779/j.issn.1009-3419.2022.102.07.
6
mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients.突变与非小细胞肺癌患者的脏层胸膜侵犯发展显著相关。
Cancer Manag Res. 2019 Mar 1;11:1945-1957. doi: 10.2147/CMAR.S195747. eCollection 2019.
7
Multidimensional communication of microRNAs and long non-coding RNAs in lung cancer.微小 RNA 和长链非编码 RNA 在肺癌中的多维通讯。
J Cancer Res Clin Oncol. 2019 Jan;145(1):31-48. doi: 10.1007/s00432-018-2767-5. Epub 2018 Nov 11.

本文引用的文献

1
Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations.国际肺癌研究协会(IASLC)/美国胸科学会(ATS)/欧洲呼吸学会(ERS)肺腺癌分类与表皮生长因子受体(EGFR)和 Kirsten 大鼠肉瘤病毒癌基因(KRAS)突变之间的关联。
Pathology. 2016 Jan;48(1):17-24. doi: 10.1016/j.pathol.2015.11.002. Epub 2015 Dec 12.
2
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.吉非替尼获美国食品药品监督管理局批准用于治疗转移性表皮生长因子受体(EGFR)突变阳性的非小细胞肺癌患者。
Clin Cancer Res. 2016 Mar 15;22(6):1307-12. doi: 10.1158/1078-0432.CCR-15-2266.
3
MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2.微小RNA-543通过靶向KRAS、MTA1和HMGA2抑制结直肠癌的生长和转移。
Oncotarget. 2016 Apr 19;7(16):21825-39. doi: 10.18632/oncotarget.7989.
4
Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.使用聚合酶链反应(PCR)结合下一代测序和桑格测序方法筛查肺腺鳞癌中的主要驱动癌基因改变。
Sci Rep. 2016 Feb 29;6:22297. doi: 10.1038/srep22297.
5
Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening.患有右肺肿瘤的老年男性吸烟者是KRAS基因突变筛查的合适对象。
Sci Rep. 2016 Jan 7;6:18566. doi: 10.1038/srep18566.
6
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.微小RNA分类器是ALK、EGFR和KRAS驱动的肺癌中强大的诊断/预后工具。
Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9. doi: 10.1073/pnas.1520329112. Epub 2015 Nov 16.
7
EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.表皮生长因子受体(EGFR)L858R突变增强肺腺癌细胞的侵袭能力,并通过激活CXC趋化因子配体12(CXCL12)-CXC趋化因子受体4(CXCR4)通路促进恶性胸腔积液的形成。
Sci Rep. 2015 Sep 4;5:13574. doi: 10.1038/srep13574.
8
Pleural involvement in lung cancer.肺癌的胸膜受累情况。
J Thorac Dis. 2015 Jun;7(6):1021-30. doi: 10.3978/j.issn.2072-1439.2015.04.23.
9
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.IASLC 肺癌分期项目:对即将发布的第八版肺癌 TNM 分类中 T 描述符修订的建议。
J Thorac Oncol. 2015 Jul;10(7):990-1003. doi: 10.1097/JTO.0000000000000559.
10
MicroRNA-135b, a HSF1 target, promotes tumor invasion and metastasis by regulating RECK and EVI5 in hepatocellular carcinoma.微小RNA-135b是热休克因子1的一个靶标,它通过调控肝癌中的RECK和EVI5来促进肿瘤侵袭和转移。
Oncotarget. 2015 Feb 10;6(4):2421-33. doi: 10.18632/oncotarget.2965.